This week, we will discuss the social media issue in Seminars of Nephrology. The discussion will be anchored by two articles - but the whole issue is up for discussion.

This week, we will discuss the fresh-off-the-press trials from this week’s issue of the NEJM: PERL and CKD-FiX. These two trials examined if the uric acid and CKD link is causal: by measuring CKD progression after giving patients allopurinol. Be ready for another medical reversal.

激活码生成器,详细教您万能激活码生成器 - 装机吧:2021-4-14 · 激活码生成器属于破解类软件，建议大家破解收费软件时只是用于自己试用，长期使用软件建议购买激活码支持正版软件，毕竟开发不易，这里分享一下激活码生成器下载。下载地址：点击下载 使用 …

SGLT2i are the wonder drug for our age. But do we know how they work? How does their natriuretic effect actually work? Let’s dig deeper into this week’s mechanistic study that explores this question

This week, we discuss the latest from CRIC, an examination of NSAIDs versus opioids for patients with CKD. Join us May 12 and 13th to discuss with #NephJC.

This week, we will not discuss anything related to COVID. We know cardiovascular disease is the cause of most morbidity and mortality in CKD. Can an invasive approach benefit our patients?

This week, as an emergency chat, we will discuss some hot-off-the-press data. Published a few days ago, the first look at what happens in the kidneys.

Steroids are the mainstay of minimal change. Or are they? Lets explore an RCT that bravely challenges the status quo of steroids with tacrolimus monotherapy

This week, we will discuss the fresh-off-the-press ISPD recommendations on what they call as ‘prescribing high quality, goal directed’ PD. No mention of adequacy even in the title, in a subtle shade at the move away from numbers to things that really matter.

This week we discuss the long awaited PEXIVAS trial. Reduced dose steroids win, and PLEX loses. Or does it?

We are now in GN territory this month - or rather ANCA Vasculitis month! First we start off with this paper from London, which uses some data from the RAVE trial along with additional experiments to show some intriguing results on the role of MPO.

In early 2000s there was an epidemic….and then it died down. Have we successfully eliminated the scourge of NSF by appropriately changing our behaviour? Perhaps the pendulum has swung too much and needs to come back to the middle.

We measure cyclosporine and tacrolimus levels. But don’t bother with mycophenolate levels - why is it? Is it too difficult? Does it not matter? NephJC tackles a different kind of study this time - a literature review, albeit conducted systematically.

The votes are in and counted. NephJC proudly presents the Top Nephrology Related stories of 2024. Note- The MENTOR trial was not included in this years voting since it made the Top stories list of 2017 when it was originally presented.

This week is a joint #DermJC and #NephJC. We will discuss two articles - here is the summary of the larger case series, from Vandana Niyyar.

This week, we will discuss a perspective peice looking at the use of race in the eGFR formulas routinely used in the hospital. #NephJC chat.